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ABSTRACT 
 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
botulinum toxin A is an effective treatment for children who have lower limb spasticity from 
cerebral palsy. 
 
STUDY DESIGN: The study by Carraro et al was a randomized double-blind clinical trial 
done in 2015.6The study done by Kim et al was a randomized, double-blind controlled 
clinical trial done in 2010.7 The study by Py et al was a clinical trial done in 2005-2006.8 
 
DATA SOURCES: Data sources obtained for this review were articles published in peer- 
reviewed journals found using PubMed Database. 
 
OUTCOMES MEASURED: The outcome measured the effectiveness of Botox and Botox 
verse Xeomin and Neuronox, as well as the improvement of Gross Motor function with the use 
of Botox and Neuronox. 
 
RESULTS: The study Carraro et al showed that incobotulinum toxin A (Xeomin) was just as 
effective for the treatment of spasticity from cerebral palsy, as onabotulinum toxin A 
(Botox).6The study by Kim et al, showed the Neuronox was just as effective as Botox.7Lastly, 
the study by Py et al, provided clear evidence that onabotulinum toxin A (Botox), was an 
effective treatment of spastic gait in cerebral palsy in the first place.8 
 
CONCLUSIONS: The results of the studies showed at Xeomin, Neuronox, and Botox all have 
similar results efficacy for the treatment of lower limb spasticity in children with cerebral palsy. 
 
KEY WORDS: Cerebral Palsy; Spastic Gait; Botox 
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INTRODUCTION 
 
Cerebral palsy is a term that is nonspecific and used to describe a chronic, static impairment 
of muscle tone, strength, coordination, or movements due to some type of cerebral insult or injury 
before birth, during delivery, or in the perinatal period.1This condition is caused by abnormal 
development of the brain or damage to the developing brain that affects the child’s ability to 
control his or her muscles.2 Even though the concept of how this condition develops is known, the 
exact cause of the disease is unknown. Cerebral palsy effects 1.5 to 4 of every 1,000 live births, 
making cerebral palsy the most common motor disability in childhood.2 It is estimated that the 
average cost of healthcare of a patient with cerebral palsy in their lifetime is $910,000.2 In 2000, it 
was estimated that the combined lifetime costs for all patients with cerebral palsy totaled $11.5 
billion in direct and indirect costs of having this condition.2 Of course, severity manifestations and 
prognosis vary substantially from patient to patient with cerebral palsy.1 
The most common form of cerebral palsy that accounts for 75% of cases involve spasticity 
of the limbs.1 Once the diagnosis is classified as spastic cerebral palsy, there is a term attached to 
the diagnosis that is used to describe the specific patients degree of spasticity. The term 
monoplegia describes the patients with one limb affected.1 Hemiplegia describes patients that 
have an arm and leg that are affected on the same side of the body, but the arm is more affected 
than the leg.1 Paraplegia describes patients that have both legs affected and both arms unaffected.1 
The last descriptive term used to describe patients with spastic cerebral palsy s quadriplegia, 
which describes a cases where all four limbs are affected equally.1 
The next most common form of cerebral palsy is ataxia, which accounts for around 15% of 
cases.1The most common way the ataxia effects the patients is in fine coordinated movement of 
the upper extremities, but may also effect the lower extremities and the trunk. Lastly, persistent 
hypotonia without spasticity accounts for 1% of cases.1 
Many different neurologic deficits tend to occur in the presence of motor deficits that are 
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caused by cerebral palsy.1 Seizures occur in up to 50% of these patients, mild retardation in 26% 
and severe retardation in up to 27%.1 Many different other disorders coexist in theses patients in 
varying degrees and combonations.1 Some commonly seen disorders are of language, speech, 
vision, hearing and sensory perception.1 
The most common finding on physical exam are those of spasticity, hyperreflexia, ataxia, 
and involuntary movements.2 Microcephaly is often present.1The patients with spastic hemiplegia 
type of cerebral palsy can present with the affected arm and leg may be smaller and shorter than the 
unaffected limbs.1 
Cerebral palsy is a clinical diagnostic term that is used to describe patients with similar 
symptoms due to a cerebral insult around birth.2 The use of laboratory and imaging tests 
depends on each patients presenting symptoms, as there is no one diagnostic test for cerebral 
palsy.1 One of the more common imaging tests done is an MRI. The MRI scan may be helpful 
in seeing the full extent of the cerebral injury and can suggest an etiology for the 
condition.1Interest is growing for genetic and metabolic testing, which can be useful to figure 
out a cause in combination with the history and MRI findings.1There are two common findings 
in a newborn that help diagnose cerebral palsy, even though they are not diagnostic.3 The first 
being the Apgar score given at 1 and 5 minutes after delivery. It has been shown that when the 
5-minute Apgar score is less than 3 the risk of neurological sequelae, such as cerebral palsy is 
increased substaintially.4Another finding in the newborn period that can support the diagnosis 
of cerebral palsy is umbilical cord blood pH less than 7 and a base deficit greater or equal to 
12.3 These findings within the umbilical cord are objective evidence for metabolic acidosis and 
the worse the acidosis, the more risk that patient has for cerebral palsy.3 
The treatment of cerebral palsy has been studied and is an area that is actively 
researched. All the treatments for cerebral palsy are directed at assisting the patient to attain 
maximum neurologic functioning with appropriate physical, occupational, and speech therapy as 
well as medications for spasticity and seizures.1 The current treatment for spastic cerebral palsy 
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includes oral antispastic drugs, intrathecal baclofen, surgical treatment such as selective dorsal 
rhizotomy and deep brain stimulation, and botulinum toxin injection. 
The efficacy regarding the use of botulinum toxin injection to increase function in 
patients with lower limb spasticity from cerebral palsy is a hot topic among healthcare 
providers. Botulinum neurotoxins are classified into seven categories: A, B, C1, D, E, F, and 
G.5The difference between the categories is their biosynthesis, size, cellular sites of action, 
binding kinetics, duration of effect and stability.5 The two types of botulinum neurotoxin that 
are currently commercially available are serotypes A and B. The mechanism of action of 
botulinum is first the toxin enters the nerves by binding to surface protein receptors and 
undergoing endocytosis into internalized vesicles.5 Then, the light chain is released into the 
nerve cytosol and the SNARE (soluble N- ethylmaleimdie-sensitive factor attachment 
protein receptor) protein complex is cleaved to inhibit exocytosis of the neurotransmitters 
such as acetylcholine.5The receptor for all types of botulinum toxin A is SV2/SNAP-25.5The 
end result is a chemodenervation of cholinergic neurons, which leads to a localized absence 
of skeletal muscle activity.5Eventually due to nerve sprouts of the chemodenervated nerves 
there is reestablished chemical contact with their targets and muscles resume activity.5The 
brand name of a specific botulinum toxin is Botox and it is a serotype botulinum toxin A.5 
Botox is the most commonly used botulinum toxin, as it is the one that has been studied most 
thoroughly.5There are many next brands of botulinum toxin that are becoming available on 
the market for use, but there are few studies that show if they are as effective as Botox. 
OBJECTIVE 
 
The objective of this selective EBM review is to determine whether or not botulinum 
toxins, besides Botox are effective for treating children who have lower limb spasticity from 
cerebral palsy. The hypothesis about the objective is that the use of other botulinum toxins are 
also an effective treatment option besides Botox, of lower limb spasticity in children with 
cerebral palsy. 
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METHODS 
 
The studies that were selected during the construction of this EBM review were two randomized 
controlled trials and one clinical trial.6,7,8 The population studied in the trials included children with 
cerebral palsy under the age of 18 and have lower limb spasticity. The interventions in each study 
involved administration of a brand of a serotype A of botulinum toxin. The first study by Py and et 
al, studied the effectiveness of Botox.8 In the study done by Carraro and et al, the effectiveness of 
Xeomin (a type of botulinum toxin A) verse Botox (a type of botulinum toxin A) was studied.6 The 
study done by Kim and et al compared the effectiveness of Neuronox (a type of botulinum toxin A) 
and Botox.7 Neuronox is not currently FDA approved for use of any condition currently in the 
United States.5The outcome measured that is of particular interest to this EBM review was the 
number of adverse effects and the improvement of functional ability of the patient. For 
clarification, each botulinum toxin in this EBM review, is in the serotype of A, but they each have 
slight individual differences.5A few notable differences between the products are the process by 
which the product is made, the complex molecular weight uniformity, and the stabilization 
solubilization pH.5 The differences are shown in the chart below: 
 Botox Xeomin Neuronox 
Nonproprietary name (FDA) Onabotulinum toxin A Incobotulinum toxin A Not FDA approved 
Process Crystallization Chromatography Chromatography 
Complex mw uniformity -900kD homogenous -150kD -150kD 
Stabilization/ solubilization pH Vacuum dried 
normal saline 
-7 
Vacuum dried 
normal saline 
-7.4 
lyophilization 
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Using PubMed databases, three studies were selected. Keywords used in the literature search 
were “cerebral palsy”, spastic gait”, and “Botox”. All articles were published in English in peer- 
reviewed journals and were selected based on significance and application, as well as the condition 
that outcomes measured were patient oriented outcomes (POEMS). Inclusion and exclusion criteria 
were similar across all three articles. Inclusion criteria involved studies that were randomized 
control trials/clinical trials, published after 2011, participations were children with cerebral palsy 
spastic subtype under the age of 18. Patients were excluded from the study if they had a history of 
anaphylactic reactions to BoNT-A, a bleeding tendency, or a history of treatment with 
anticoagulants, aminoglycosides, muscle relaxants, parasympathetic antagonists, or dopaminergic. 
Individuals who have previously undergone surgery on the muscles or ligaments of the lower 
extremities who had fixed contracture of the lower limb joints or who exhibited severe athetoid 
movements were also excluded. Table 1 demonstrates the demographics of the studies included in 
this EBM review. The statistic used in all the studies was the p-value. 
Table 1: Demographics & Characteristics of included studies 
 
Study Type #pts Age Inclusion Criteria Exclusion Criteria W/D Interventions 
Carraro3 RCT 35 3-18 
years 
old 
Patients had to have a 
diagnosis of spastic 
diplegia, hemiplegia or 
quadriplegia due to CP, 
as verified by history, 
clinical/instrumental 
examination and 
neuroimaging findings; 
they were between 3 
and 18 year of age. 
Subjects were excluded from the 
study if was present one of the 
following criteria: peripheral nervous 
system disorders/ myopathies; 
previous treatments for spasticity 
other than BTX-A to the lower limbs 
(<1 years); previous orthopedic 
surgery to lower extremities; bone or 
joint deformities and fixed 
contractures; medications that could 
have had an impact on the study 
findings (es. Intrathecal baclofen, 
benzodiazepines, muscle relaxant). 
0 Botox and 
incobotulinum 
Kim4 RCT 119 2- 10 Childrenwho hada Patients were excluded from the study if they 5 Neuronox and 
   years diagnosisof CP, were had a history of anaphylactic reactions to  Botox 
   old aged between2 and 10 BoNT-A, a bleeding tendency, or a history   
    years, and who were of treatment with anticoagulants,   
    classified as Gross aminoglycosides, muscle relaxants,   
    Motor Function parasympathetic antagonists, or   
    Classification System dopaminergic. Individuals who have   
    (GMFCS) level I, II, or previously undergone surgery on the muscles   
    III were eligible for or ligaments of the lower extremities who   
    participation inthe had fixed contracture of the lower limb joints   
    study. They hadto or who exhibited severe athetoid movements   
    show tiptoeing gait asa were also excluded.   
    resultofspasticcalf    
    musclesandbeableto    
    receivephysio- therapy    
    followinga    
    standardized protocol    
    for lowerlimb    
    spasticity. The    
    participants were    
    recruited from    
    individuals who visited    
    the outpatient    
    departments of the    
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    university hospitals 
because of lower limb 
spasticity resulting 
from CP. 
   
Py A-G5 Clinical 
trial 
54 Under 
18 y/o 
During the period 
from May 2005 to May 
2006, all the 
ambulatory children 
examined in outpatient 
consultations in 
the spastic diplegia 
service, consequential to 
periventricular 
leukomalacia lesions for 
which the examining 
doctor recommended an 
injection of botulinum 
toxin in the lower limbs, 
were seen by the senior 
doctor in the service 
who, after a clinical 
examination, confirmed 
or rejected the examining 
doctor’s recommendation 
and suggested injection 
sites. The injection site 
could be a single or 
multiple. 
children who had surgery less than three 
months previous, and children who were 
not re- evaluated one month after their 
surgery due to distance concerns. 
0 Ultrasound 
guidance of 
the botulinum 
toxin injection 
 
 
OUTCOMES MEASURED 
 
Outcomes measured were those of patient-oriented evidence that matters (POEMS). The 
articles all measured outcomes in different ways. Kim and et al and Py and et al, measured 
outcomes on the Gross Motor Function measure scale. Carraro and et al measured the outcomes 
by a checklist given to the patient’s parents that measured the adverse effects of the treatment. 
The outcomes measured were the number of adverse effects. 
 
 
RESULTS 
 
Two randomized, controlled trials, and one clinical trial were analyzed in this review. 
Each study compared the effectiveness of different versions of botulinum toxin serotype A in 
children under the age of 18 with lower limb spasticity due to cerebral palsy. 
The study done by Py at el was done to show the effectiveness of Botox (onabotulinum 
toxin).8 The study included all ambulatory children examined in outpatient consultations in the 
spastic diplegia service, from May 2005 to May 2006.8There were 54 children under 18 with 
diplegia spastic gait cerebral palsy that participated in the study.8 In order to determine the 
injection site of each individual, every child had a visual gait examination and a functional 
evaluation done using the Gross Motor Function Measure.8 The product used was Botox 
Terrell, Botulinum Toxin and Cerebral Palsy 7 
 
produced by Allergan Labatory.8The dose was between 5 and 6 UI/kg, according to the marketing 
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recommendation for each different muscle.8The dilution of 100 units, was carried out in 1 to 2 ml 
of 0.09% physiological serum, with a minimal volume of 0.3mL per injection.8 Of the 54 children 
given Botox injections in their lower limbs, 85% of them were evaluated with the GMFM before 
and after the injections.8The remaining 15% either had difficulty understanding the instructions or 
were opposed to treatment during the procedure.8 Only one undesirable effect was reported by the 
patients.8 The overall clinical effectiveness was good in 51% of the children.8The clinical 
improvement was better in cases of injections to the hamstring muscle (57%) and/or the 
gastrocnemius muscle 57%.These findings show a significant p-value of 0.04.8 The best clinical 
improvement was in children under 6 (53%) and over 12.8The effectiveness of the treatment all 
increased with increased doses.8 Patients injected with over 0.8IU/kg per muscle was statically 
significantly better than injection doses of under 0.8 UI/kg per muscle, the p-value was < 0.05.8 
Overall there was a 24% improvement of the GMFM scores in the children treated.8 
In the study by Carraro et al6 there were 35 patients recruited and the study was 
performed at an institute for rehabilitation and treatment.6 All patients completed the study and 
they were all treated by the same physician.6 All the patients had the diagnosis of spastic 
diplegia, hemiplegia, or quadriplegia due to cerebral palsy, as verified by history, 
clinical/instrumental examination and neuroimaging findings. All the participants were between 
the ages of three and eighteen.6 All the participants in the study had clinical indication to have 
treatment with BTX-A in the gastrocnemius muscle.6The participants were randomized to either 
the study group (incobotulinum toxin A) or the control group (onabotulinum toxin A). Both of 
the groups were injected with 5units/kg on the gastrocnemius (medialis and lateralis) muscles 
with a clinical conversion ratio of 1:1 for onabotulinum toxin A and incobotulinum toxin A.6 
The study group had a total of 17 participants, and the control group had 18 participants.6 The 
two groups were well balanced regarding demographics.6 All adverse events were recorded by 
the patient’s parents in the form of a checklist at baseline, 48hours after procedure, 10 days 
after, and 3 months after.6 The checklist had the most common side effects listed such as fever, 
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fatigue, general and local muscle pain, diarrhea, ecchymosis.6 The form also had a blank area 
for parents to add any additional side effects that their child experienced.6The adverse effects 
were define as “severe” if they were fatal or life-threatening or if they resulted in functional 
disability or hospitalizations of the patient.6The adverse effect was termed “local” if they were 
confined to the site of the injection.6 Throughout the study there were no severe adverse effects 
noted by any of the parents of the participants. The most common “local adverse effect was 
fatigue among the study and control group.6 Table 2 demonstrates the statistical information 
from the study. 
Table 2:Frequency of local adverse events6 
 
 Within 
the first 
48hours 
  Within 
the first 
10 days 
  Within 
the first 
3 months 
  
At Least 
one local 
adverse 
event 
Study 
group 
Control 
group 
P values Study 
group 
Control 
group 
P values Study 
group 
Control 
group 
P values 
 6 7 0.56 8 6 0.72 0 3 0.11 
 
As shown by the results in the table 2, the study group (incobotulinum toxin A) and the control 
group (onabotulinum toxin A) had similar numbers of adverse effects with slightly less adverse 
effects within the study group overall. 
The study done by Kim et al, included 127 total children with cerebral palsy, who 
presented at three university hospitals with lower limb spasticity.7 The 127 children were then 
assessed for eligibility and 119 were eligible.7 The study was done to access the difference of 
adverse events and effectiveness of Neuronox compared with Botox for the treatment of lower 
limb spasticity in cerebral palsy.7The mean age of the participants was 4.33 years old, and the 
study had 43 females and 76 males.7Participants were randomly assigned to a treatment group. 
60 patients were treated with Neuronox and 59 with Botox.7 Each group received the treatment 
in the calf muscles at a dose of 4U/kg for those with hemiplegia (40) and 6U/kg of those patients 
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with diplegia (79).7 All participants were treated by experienced physicians.7Assessments were 
performed at baseline (V1), and a 4(V2), 12(V3), and 24(V4) weeks.7The outcomes were 
measured by using the Gross Motor Function Measure 88 (GMFM-88), and was measured at 
baseline and every other interval.7 After the treatments the GMFM scores increased significant 
at all follow up visits.7 The Neuronox group showed a mean increases of 2.14 at V2, 3.77 at V3, 
and 4.76 at V4.7 The botox group showed mean increases of 2.65 at V2, 5.25 at V3, and 6.63 at 
V4.7 There was no significant difference in the change in the GMFM scores between the 
treatment groups at V2, p=0.41.7 At V3 and V4, Botox showed a larger increase in the GMFM 
score than the Neuronox group , p=0.03.7 The frequency of adverse events was not significantly 
different between the two groups. The 119 participants that underwent the original evaluation, 
101 completed the study without violation of protocol.7 Eight individuals in the Neuronox group 
were excluded after the intervention, one due to adverse events, two retracted their consent, 
three didn’t attend the scheduled follow up, and two were classified as protocol violators.7Six 
individuals in the Botox group were excluded after the intervention, one was excluded because 
of an adverse outcome, four retracted their consent, and one didn’t attend the scheduled follow 
up.7Also, two individuals in each group were excluded after the final evaluation because of 
violation of study protocol.7 According to the study Neuronox is not inferior to Botox.7 
Neuronox is not currently FDA approved in the United States. 
DISCUSSION 
 
The study by Py et al, showed that Botox is an effective treatment for diplegia spastic gait cerebral 
palsy. The reasoning for the best clinical improvement found in children under six can be explained 
by the fact that the fibrotic and retractile phenomena are less significant in younger children, 
allowing the effects of the treatment to be noted at a greater extent.8It can also be explained by motor 
development being greater in that study population, so when the problematic spasticity is eliminated 
there is a more rapid influence in overall function.8 The effectiveness of the treatment was also better 
in children over 12, which was more surpsing.8 This could be explained by that fact that many of the 
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children over 12 have already had musculotendinous surgical treatment in their lower limbs, which 
helped the practitioner target more precisely the muscles to be injected.8 The main limitation of this 
study is that it was not a double-blind study, which in turn makes the results less reliable.8Two more 
limitations to the study include that the post-evaluation took place at 3 to 4 weeks after the injection, 
which could have been too early to see complete results, and the percent of improvement could have 
been lower in the patients where the dose of the injection was lower per muscle, due to multiple 
muscle injections and the cumulative dose for all participants being 6IU/kg of botox.8 
 
The study by Carraro et al showed that incobotulinum toxin A doesn’t have more 
adverse effects and is equally beneficial as onabotulinum toxin A.6 The study did not detect 
any important difference in safety between these two formulations of BTX-A for the 
treatment of lower limb spasticity in children under 18 with cerebral palsy.6 The study as a 
whole produced an increase in adverse events relative to other similar studies.6 Within the 
whole cohort at 48 hours, 48.6% of patients experienced an adverse event, 47.8% in the first 
ten days and 11.8% in the first three months.6 There were a few limitations to the study. The 
first being that there was no placebo group, which means that not all adverse events can be 
directly linked to the treatment.6 Another limitation of the study is that the parents were 
given an articulated list of adverse events, which could have caused the patients to believe 
that a certain symptom was from the treatment only because it was listed on the form.6 The 
last limitation of this study was the small sample size that participated in the treatments.6 At 
this point, incobotulinum toxin A is not currently being used in the United States for 
treatment of spastic gait cerebral palsy but this study does show that it could have a place in 
the treatment of this condition in the future.6 Further studies need to be done to confirm the 
safety and effectiveness of incobotulinum toxin A. 
The study by Kim et al, showed Neuronox to be just as effective as Botox. The study as a 
whole showed improvement in all children treated in both treatment groups for lower limb spasticity 
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from cerebral palsy.7The results of this study are similar to those of previous studies done on Botox.7 
The study had a few notable limitations that could have altered the results. One limitation was that 
the study was not controlled with a placebo group, which is necessary in order to show the net effect 
of the drug.7 Another limitation of the study was that the protocol did not apply variable doses of 
either treatments.7 According to the severity of each patient’s spasticity, different doses would 
produce more optimal outcomes.7The dose of 4U/Kg could have been insufficient in some cases.7 
This study was the first well designed, strictly conducted phase III clinical trail to validate the 
effectiveness of Neuronox for lower limb spasticity in cerebral palsy.7The results of this study are 
expected to provide physicians with more choices for the treatment of spasticity in cerebral palsy in 
the future.7 
CONCLUSION 
 
The trials analyzed in this EBM review showed that the different types of botulinum toxin 
A all showed significant improvement in the treatment of lower limb spasticity from cerebral 
palsy.6,7,8, The study Carraro et al showed that incobotulinum toxin A (Xeomin) was just as 
effective for the treatment of spasticity for cerebral palsy, as onabotulinum toxin A(Botox).6 The 
study by Kim et al, showed the Neuronox was just as effective as Botox.7 Lastly, the study by Py 
et al, provided clear evidence that onabotulinum toxin A (Botox), was even an effective treatment 
of spastic gait in cerebral palsy in the first place.8 
Future study is warranted to definitively evaluate the efficacy of different types of 
botulinum toxin A in the treatment of lower limb spasticity in cerebral palsy. All of the 
aforementioned studies have a small population size and various limitations that reduce the 
significance of the results. Additional studies should include a larger population and should be 
double-bind trials to make the results more reliable. This treatment should be continually 
investigated because it could change the treatment options for children with issues of lower 
limb spasticity from cerebral palsy. 
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